Format

Send to

Choose Destination
J Neuroimmunol. 2013 Aug 15;261(1-2):123-8. doi: 10.1016/j.jneuroim.2013.05.009. Epub 2013 Jun 22.

Cerebrospinal fluid and serum JC virus antibody detection in multiple sclerosis patients treated with natalizumab.

Author information

1
Tisch Multiple Sclerosis Research Center of New York, 521 West 57th Street 4th Fl., New York, NY 10019, USA.

Abstract

Progressive multifocal leukoencephalopathy (PML) is a complication of natalizumab treatment. In order to identify natalizumab-treated patients at risk of developing PML, we assayed for anti-JC virus (JCV) antibody levels in cerebrospinal fluid (CSF). Serial CSF antibody levels were obtained, with 4 patients showing increases in anti-JCV levels indicating possibly viral activation. In patients with both CSF and serum antibody levels, a comparison showed only a moderate Spearman Rank Correlation Coefficient of 0.38. Our data suggests that serum anti-JCV antibody testing alone may not suffice in identifying at-risk patients because of the lack of uniform correlation with CSF titers.

KEYWORDS:

Cerebrospinal fluid; JCV; Multiple sclerosis; Natalizumab; PML; Tysabri

PMID:
23800458
DOI:
10.1016/j.jneuroim.2013.05.009
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center